Financial incentives and physicians' prescription decisions on the choice between brand-name and generic drugs: Evidence from Taiwan

Journal of Health Economics

Volumn 28, Issue 2, 2009, Pages 341-349

  Liu, Ya Ming ^a   Yang, Yea Huei Kao ^b   Hsieh, Chee Ruey ^c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b Institute of Biomedical Science   (Taiwan)

^c INSTITUTE OF ECONOMICS   (Taiwan)

Author keywords

Brand name drugs; Generic drugs; Incentives; Prescription decision; Price regulation

Indexed keywords

COST-BENEFIT ANALYSIS; DECISION ANALYSIS; DIABETES; DRUG; FINANCIAL SERVICES; HEALTH SERVICES; HYPOTHESIS TESTING; INCENTIVE; PRICING POLICY; PROFITABILITY;

AGED; DRUG PRESCRIPTIONS; DRUGS, GENERIC; EVIDENCE-BASED PRACTICE; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; PHYSICIAN INCENTIVE PLANS; PHYSICIAN'S PRACTICE PATTERNS; TAIWAN;

ASIA; EURASIA; FAR EAST; TAIWAN;

EID: 62049084257     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2008.10.009     Document Type: Article

References (19)

1. Cheng C., and Hsieh C.R. Economic analysis of NHI pharmaceutical policies and drug expenditures. Socioeconomic Law and Institution Review 35 (2005) 1-42 (in Chinese)
2. Coscelli A. The importance of doctors' and patients' preferences in the prescription decision. Journal of Industrial Economics 48 (2000) 349-369
3. Danzon P.M., and Chao L.W. Does regulation drive out competition in pharmaceutical markets?. Journal of Law and Economics 42 (2000) 311-357
4. Danzon P.M., and Furukawa M. Prices and availability of pharmaceuticals: evidence from nine countries. Health Affairs Web Exclusive W3 (2004) 521-536
5. Danzon P.M., et al. The impact of price regulation on the launch delay of new drugs: evidence from 25 markets in the 1990s. Health Economics 14 (2005) 269-292
6. Duggan M.G. Hospital ownership and public medical spending. Quarterly Journal of Economics 115 (2000) 1343-1373
7. Grabowski H.G. Competition between generic and branded drugs. In: Sloan F.A., and Hsieh C.R. (Eds). Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective (2007), Cambridge University Press
8. Hellerstein J.K. The importance of the physician in the generic versus trade-name prescription decision. Rand Journal of Economics 29 (1998) 108-136
9. Hsieh, C.R., forthcoming. Pharmaceutical policy in Taiwan. In: Eggleston, K. (Ed.), Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacific. Brookings Institution Press.
10. Hsieh C.R., and Sloan F.A. Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective?. Value in Health 11 (2008) 334-344
11. Hynes D.M., et al. Adherence to guidelines for ESRD anemia management. American Journal of Kidney Disease 47 (2006) 455-461
12. Iizuka T. Experts' agency problems: evidence from the prescription drug market in Japan. Rand Journal of Economics 38 (2007) 844-862
13. Jacobson M., et al. Does reimbursement influence chemotherapy treatment for cancer patients?. Health Affairs 25 (2006) 437-461
14. Kyle M.K., et al. Does reimportation reduce price differences for prescription drugs? Lessons from the European Union. Health Services Research 43 (2008) 1308-1324
15. Lundin D. Moral hazard in physician prescription behavior. Journal of Health Economics 19 (2000) 639-662
16. McGuire T. Physician agency. In: Culyer A.J., and Newhouse J.P. (Eds). Handbook of Health Economics. vol. 1A (2000), North Holland, Amsterdam
17. O'Malley A.J., et al. Impact of alternative interventions on changes in generic dispensing rates. Health Services Research 41 (2006) 1876-1894
18. Reiffen D., and Ward M.R. Generic drug industry dynamics. Review of Economics & Statistics 87 (2005) 37-49
19. WHO Collaborating Center for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. 7th edition (2004), Norwegian Institute of Public Health, Oslo, Norway